SHR-1222

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Second Xiangya Hospital of Central South University

Conditions

OsteoporosisOsteoporosis, Osteopenia

Phase 1

The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects

CompletedNCT03870100

Jiangsu HengRui Medicine Co., Ltd.Osteoporosis

Start: 2019-04-15End: 2020-01-06Updated: 2020-06-16

A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients

CompletedNCT04435158

Jiangsu HengRui Medicine Co., Ltd.Osteoporosis

Start: 2020-08-25End: 2022-07-18Updated: 2023-07-06

Unknown Phase

Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass

CompletedNCT03898024

Second Xiangya Hospital of Central South UniversityOsteoporosis, Osteopenia

Start: 2019-04-15End: 2020-08-15Updated: 2022-06-30

Related Papers

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study

Frontiers in Pharmacology2021-10-207 citations